This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 10/09/2026
Tucciarone et al (2026)22conducted a randomized, double-blind, placebo-controlled trial to evaluate whether low-dose buprenorphine prolongs the antisuicidal effects observed after IV ketamine administration in adults with MDD or bipolar II disorder. Following a single open-label IV ketamine infusion (0.5 mg/kg over 40 minutes), patients were randomized 1:1 to receive sublingual buprenorphine (0.2-0.8 mg/day; n=23) or matched placebo (n=22) for 4 weeks beginning 48 hours after ketamine administration. Patients were included if they had a Scale for Suicidal Ideation (SSI) total score ≥6. Patients with a history of opioid use disorder, current or chronic opioid use, or substance use disorder (excluding nicotine) within 6 months before screening were excluded. The primary endpoint was the change in SSI total score, assessed weekly from day 1 to day 31.
Fifty patients were treated with IV ketamine, with SSI scores decreasing from day 1 to
day 3 (mean change, -9.1; SD=6.6; P<0.001). All randomized patients had MDD. Both treatment groups demonstrated significant reductions in SSI total scores on day 31. Greater improvement was observed in the ketamine+buprenorphine group (mean change, -11.6; SD=5.8) than in the ketamine+placebo group (mean change, -6.3; SD=7.0), with a significant treatment-by-time interaction (P<0.001). By day 31, 78% of patients receiving ketamine+buprenorphine and 48% receiving ketamine+placebo achieved a ≥50% reduction in SSI score (P=0.035). Statistically significant reductions in Montgomery-Åsberg Depression Rating Scale (MADRS) total scores were observed in both groups; however, the difference between groups was not statistically significant (treatment-by-time interaction, P=0.104). No serious treatment-related adverse events were reported. The most frequently reported adverse events in the buprenorphine and placebo groups, respectively, were dizziness (21.7% vs 0%), oral burning (17.4% vs 0%), headache (17.4% vs 22.7%), and nausea (13.0% vs 0%).
Limitations include the relatively small sample size (60 patients were needed to achieve 80% power, which was not reached), potential for treatment expectancy effects, exclusion of patients with substance use disorder, and the inability to determine whether the response to ketamine predicted response to buprenorphine.
Yoon et al (2025)20reported results from a 4-week, randomized, double-blind trial (N=58) that compared IV ketamine (0.5 mg/kg weekly × 4 infusions) plus intramuscular (IM) naltrexone (380 mg before the first infusion; n=20), ketamine (0.5 mg/kg) plus saline (n=19), and midazolam (0.045 mg/kg; active control for ketamine) plus saline (n=19) in patients with MDD and AUD. All patients received standard of care regimens in addition to these treatments. Clinical response and alcohol abstinence rates were co-primary endpoints.
Clinical response, defined as a ≥50% reduction in MADRS score at 240 minutes post-final infusion, was observed to be high across groups: ketamine+naltrexone (93.8%), ketamine+saline (81.8%), and midazolam+saline (86.7%). Remission (MADRS <10) rates were similarly high, at 87.5%, 81.8%, and 73.3%, respectively. One-week post-treatment, MADRS scores remained significantly lower in both ketamine groups versus midazolam. Alcohol abstinence rates throughout the 4-week treatment period were not significantly different (40.9%, 63.5%, and 38.5% respectively). Adverse events were observed in 14 patients (73.7%) in the midazolam-saline group, 14 patients (70.0%) in the ketamine-naltrexone group, and 11 patients (57.9%) in the ketamine-saline group. No study-related serious adverse events occurred; most adverse events were mild to moderate. Limitations include small sample size; weekly infusion schedule and limited assessment timepoints may underestimate peak ketamine effects; findings may not be generalized to a population of patients with MDD alone and did not adjust for multiplicity. The authors stated that although findings appeared to question the role of opioid receptors in the antidepressant effects of ketamine, the results should be interpreted with caution as there was a lack of separation from the control group in the co-primary endpoints.
Jelen et al (2025)19 conducted a randomized, double-blind, placebo-controlled crossover study (N=26) in adults with MDD to assess the impact of opioid receptor antagonism on ketamine response. Participants received oral naltrexone (50 mg) or placebo (ascorbic acid 50 mg) prior to IV ketamine (0.5 mg/kg over 40 min), with a 2–4 week washout between sessions. Usual psychotropic medications were received during the study.
Based on proton magnetic resonance spectroscopy (1H-MRS) of 24 patients, naltrexone pretreatment significantly attenuated ketamine-induced glutamatergic activity in the anterior cingulate cortex, as measured by the ratio of glutamate and glutamine to the total N-acetylaspartate (Glx/tNAA: F₁,₂₅₃=4.83, P=0.029) and reduced the antidepressant effect as measured by MADRS at day 1 (mean difference vs placebo=4.15; F₁,₇₄=5.39, P=0.023; Cohen’s d=0.60). No significant differences were observed for Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR), Maudsley 3-item Depression Visual Analogue Scale (M3VAS), or anhedonia scales (Snaith-Hamilton Pleasure Scale [SHAPS], Temporal Experience of Pleasure Scale, [TEPS]) across the two treatment groups at day 1. Dissociation and psychotomimetic effects were similar (Clinician-Administered Dissociative States Scale [CADSS]: F₁,₂₅=0.003, P=0.959). There were no significant differences in adverse event (AE) rates between the two groups, with the most commonly reports AEs (≥10% in either arm) being dissociation, headache, dizziness, nausea, vomiting, and lethargy. No serious adverse events were reported. Limitations include small sample size and short follow-up; no placebo-infusion arm and possible carryover effects; results may not generalize beyond racemic ketamine or a more treatment resistant patient population; using 1H-fMRS with 3 Tesla may not reliably differentiate glutamate and glutamine.19,24
Williams et al (2018 and 2019)18,25
The interpretability of these findings is limited by the study design, including a lack of a control arm necessary to assess the effects of naltrexone alone or placebo alone (which is considered relevant since endogenous opioid peptide signaling of MOR have been associated with positive mood responses to placebo),26
Yoon et al (2019)17 evaluated the use of naltrexone pretreatment with ketamine in patients with MDD and alcohol use disorder. This 8-week, open-label, pilot study included 5 patients who received injectable naltrexone (380 mg once as an extended-release formulation, 2-6 days prior to the first ketamine infusion) and repeated IV ketamine infusions (0.5 mg/kg once a week for 4 weeks for a total of 4 treatments). Clinical response, defined as a ≥50% improvement in the MADRS scores from baseline to 4 hours post-infusion, was met by 60% of patients after the initial ketamine dose and by 100% by the fourth dose. No serious side effects were reported. The authors concluded that naltrexone pretreatment does not appear to interfere with the antidepressant effects of ketamine.
Marton et al (2019)21 conducted a retrospective analysis of treatment outcome data of 40 veterans with TRD who were treated with up to 6 infusions of ketamine (0.5 mg/kg over 40 minutes) twice weekly for 3 weeks. During the treatment period, 7 patients received MOR agonists (buprenorphine [n=5], methadone [n=2]) for >12 months, 1 patient received long-acting injectable naltrexone, and 27 patients were not on opioidergic drugs. While the results demonstrated significant reductions (P<0.001) in Beck Depression Inventory-II scores over the 6 infusions of ketamine treatment, no difference was found between the MOR agonist and non-MOR agonist groups pre- and post-treatment. A similar antidepressant response was seen in the one patient receiving naltrexone.
Manza et al (2025)23 presented a case series (N=3) as a feasibility study in patients with severe, chronic opioid use disorder (OUD) and comorbid depression initiating methadone treatment. Within one month of methadone initiation, participants received six IV ketamine infusions (0.5 mg/kg over 40 minutes) administered thrice a week for two weeks.
All three patients completed the ketamine regimen and remained in methadone treatment at 3-month follow-up. Methadone dosing records showed two patients achieved 100% adherence and one achieved 81% (73 of 90 doses). Depression symptoms decreased by >12 points on MADRS in all cases. Self-reported depression symptoms decreased in 2 patients from severe to mild/moderate, and one from moderate to remission. Two shifted from severe to mild/moderate, and one from moderate to remission. All participants reported reductions in opioid craving and improvements in sleep quality; two reported fewer life problems related to drug use. Adverse events were mild or moderate, most commonly transient hypertension during infusions; no serious adverse events occurred. Dissociative effects were minimal, though each patient reported at least one session with moderate ratings of “wanting more” ketamine.
A literature search of MEDLINE®
| 1 | European Medicines Agency (EMA). Committee for Medicinal Products for Human Use (CHMP). SPRAVATO assessment report. Procedure No. EMEA/H/C/004535/0000. 2019- [cited 2024 March 12]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/spravato-epar-public-assessment-report_en.pdf. |
| 2 | |
| 3 | |
| 4 | |
| 5 | |
| 6 | |
| 7 | |
| 8 | |
| 9 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 23 | |
| 24 | |
| 25 | |
| 26 |
Would you like to clear and leave your conversation? Message history will be lost.